Cecilia Bergeria
Johns Hopkins School of Medicine · Johns Hopkins University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Cecilia Bergeria as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:02 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06089707 · Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use FentanylUniversity of Maryland, Baltimore · active not recruiting · Opioid Use Disorder · principal investigator
- Ph2NCT05511909 · Evaluating Buspirone to Treat Opioid WithdrawalUniversity of Maryland, Baltimore · recruiting · Opioid Use Disorder, Opioid Withdrawal, Opioid Craving · principal investigator
- Ph1NCT05324982 · Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy ParticipantsUniversity of Maryland, Baltimore · completed · Behavioral Pharmacology of Cannabis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Validating an Opioid Craving Assessment for FDA Qualification as a Drug Development ToolUG3DA062905 · NIDA · JOHNS HOPKINS UNIVERSITY · fiscal years 2025 to 2026 · $515,219 awarded in 2026Same name and institution; not confirmed by an ID
- Developing a Clinical Outcome Assessment for Opioid Craving Using Patient Feedback (DDT-COA-000138)U01FD008072 · FDA · JOHNS HOPKINS UNIVERSITY · fiscal years 2023 · $249,964 awarded in 2023Same name and institution; not confirmed by an ID
- Developing a Clinical Outcome Assessment for Opioid CravingR21DA054952 · NIDA · JOHNS HOPKINS UNIVERSITY · fiscal years 2021 to 2022 · $204,688 awarded in 2022Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:02 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- Addiction Potential of Cigarettes With Reduced Nicotine Content in Populations With Psychiatric Disorders and Other Vulnerabilities to Tobacco Addiction.JAMA Psychiatry · 2017113 citationsRCR 6.5
- Changes in Cigarette Consumption With Reduced Nicotine Content Cigarettes Among Smokers With Psychiatric Conditions or Socioeconomic Disadvantage: 3 Randomized Clinical Trials.JAMA Netw Open · 202069 citationsRCR 5.1
- Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.Sci Transl Med · 202266 citationsRCR 7.0
- Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.J Anal Toxicol · 202234 citationsRCR 4.1
- Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model.Neuropsychopharmacology · 202129 citationsRCR 2.7
- Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype-genotype assessment.Addict Biol · 202415 citationsRCR 4.4
- Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic pain.Neuropsychopharmacology · 202312 citationsRCR 2.2
- Evaluating the utility of the modified cigarette evaluation questionnaire and cigarette purchase task for predicting acute relative reinforcing efficacy of cigarettes varying in nicotine content.Drug Alcohol Depend · 201911 citationsRCR 0.8
- 5 citationsRCR 2.5
- A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.Exp Clin Psychopharmacol · 20234 citationsRCR 0.7